Programs
Pipeline
Underpinned by the invention of our proprietary CriPec® nanomedicines, we are developing next generation treatments for cancers and other diseases with high unmet medical needs and progressing these into the clinic.
Cristal Therapeutics is progressing a robust pipeline of nanoparticle therapeutic candidates which are rationally designed to target specific tissues, cells and intracellular components throughout the body.
Our proprietary in-house programs are focused on cancer:
CPC634
The Company’s lead candidate, CPC634 is in a Phase 2 clinical study to examine its therapeutic efficacy in the treatment of patients with ovarian cancer and solid tumours.
CPC205
We are also developing CPC205, a PET radiotracer variant of CPC634, which is being evaluated in clinical studies. CPC205 is enabling the molecules’ biological fate to be tracked in real time in humans and also allowing non-invasive quantification of tumour uptake. CPC205 has the potential to be used as a companion diagnostic tool to support a personalized healthcare approach.
CPC879
CPC879 is a CriPec®-based nanoparticle that incorporates therapeutic oligonucleotides and is aimed at precisely and effectively targeting the right subcellular compartment in cancer tissue.
Our inflammation program, CPC289 is available for licensing.
CPC289
CPC289 is centred on a CriPec®-based nanoparticle that entraps dexamethasone, an approved corticosteroid therapeutic for the treatment of inflammation. In vivo proof-of-concept was achieved in two models of chronic inflammation. This exciting application of the CriPec® technology is available for licensing.
CriPec®-based nanomedicines are new drug modalities with the following key properties.
Therapeutic outcome
- The potential to achieve improved therapeutic outcomes including superior efficacy and higher tolerability in comparison with conventional treatment modalities.
Pharmaceutical features
- Small, tuneable whilst uniform in size.
- Offer high loading, tuneable drug release profiles and are biodegradable.
- Have excellent stability during storage.
- Fully scalable, easily manufactured to cGMP standards using a robust 2-3 step proprietary process and low-cost system.
Biological profile and Mode of Action
- Demonstrated enhanced target accumulation and selective drug exposure over time in preclinical in vivo studies.
- CriPec® based nanomedicines can be engineered to passively or specifically target defined cells or tissue in the body and concentrate a drug payload at the disease site while minimizing adverse effects on healthy tissues.
- Long circulation
- Excellent safety profile of nanoparticles themselves
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
